Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 719-726

  O'Connor, Owen A ^a   Portlock, Carol ^b   Moskowitz, Craig ^b   Hamlin, Paul ^b   Straus, David ^b   Gerecitano, John ^b   Gonen, Mithat ^b   Dumitrescu, Otilia ^b   Sarasohn, Debra ^b   Butos, John ^b   Neylon, Ellen ^a   Cortelli, Barbara Mac Gregor ^a   Blumel, Susan ^c   Evens, Andrew M ^d   Zelenetz, Andrew D ^b   Wright, John ^e   Cooper, Brenda ^f   Winter, Jane ^d   Vose, Julie ^c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BORTEZOMIB; CREATININE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; LEUKOCYTE; LYMPHOCYTOMA; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUTROPHIL; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; BORONIC ACIDS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PYRAZINES; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 74549164108     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2647     Document Type: Article

References (27)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
2. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
3. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-9.
4. Tsujimoto Y, Gorham J, Cossman J, et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-3.
5. O'Connor OA, Smith EA, Toner LE, et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006;12:2902-11.
6. Kitada S, Takayama S, De Riel K, et al. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994;4:71-9.
7. Paoluzzi L, Gonen M, Toner L, et al. Targeting antiapoptotic BcL-2 family members with AT-101 in pre-clinical models of aggressive lymphoma in combination with cyclophosphamide (C) and rituximab (R) produces a marked improvement in therapeutic efficacy. Blood 2005:106.
8. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166-73.
9. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
10. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor α response with clinical activity. J Clin Oncol 2006;24:2105-12.
11. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75.
12. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-74.
13. Belch A, Kouroukis T, Crump M, et al. Phase II trial of bortezomib in mantle cell lymphoma. Blood 2004;104:Abstract 608.
14. Cheson BD, Horning SJ, Coiffier B, et al. NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244.
15. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
18. Kukreja A, Hutchinson A, Mazumder A, et al. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications. Br J Haematol 2007;136:106-10.
19. Subklewe M, Sebelin-Wulf K, Beier C, et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 2007;68:147-55.
20. Naujokat C, Berges C, Hoh A, et al. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology 2007;120:120-32.
21. Kuppers R. Prognosis in follicular lymphoma - it's in the microenvironment. N Engl J Med 2004;351:2152-3.
22. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
23. Heckman CA, Mehew JW, Boxer LM. NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002;21:3898-908.
24. Marshansky V, Wang X, Bertrand R, et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001;166:3130-42.
25. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001;3:173-82.
26. De Vos S, Dakhil SR, McLaughlin P, et al. Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: final results. ASH Annual Meeting Abstracts 2006;108:Abstract 694.
27. O'Connor O, Hamlin P, Moskowitz CH, et al. Schedule of bortezomib administration may be an important determinant of single agent activity in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma, 2007 - ASCO Abstract for Presentation.